EVERSANA™ and Experic are pleased to announce that they will be partnering to aid life sciences companies in optimising clinical development, manufacturing, launch planning and commercialisation efforts.

EVERSANA is a pioneer of next-generation commercial services to the life sciences industry.

Under the terms of the partnership, Experic’s clinical and commercial-scale manufacturing and packaging services will be available within EVERSANA’s fully integrated services platform, which is currently under contract to manage multiple product launches across diverse therapeutic indications. In 2021, the expanded services will be used in the complete commercialisation of new products or to revitalise the market position and performance of existing branded therapies.

“We built EVERSANA to break down the inefficient service silos that traditionally exist in this industry. Our fully integrated platform is complemented with best-in-breed partnerships – each designed to expedite the development, launch and value of much-needed therapies,” said Greg Skalicky, Chief Revenue Officer, EVERSANA. “Experic is the contract manufacturing organisation designed with innovators in mind. Together, we streamline development through commercialisation and create visibility at each stage of the process.”

“We are thrilled to work with the EVERSANA team. Together we offer smart solutions for pharmaceutical companies transitioning products to commercialisation,” said Jeffrey P. McMullen, Chairman and CEO, Experic. “It is a unique combination of expertise and services that can ensure the long-term success of our customers’ products.”

Both companies’ clients will have broader access to end-to-end outsourced services and innovative contracting models to propel product journeys and improve patient experiences. EVERSANA’s integrated or stand-alone pharmaceutical services span all disciplines, including global pricing, market access, clinical and commercial field forces, compliance, patient support, product delivery, and data and analytics. Experic supports every phase of a product’s life cycle from clinical to commercial scale, across a range of dosing and packaging formats, including capsule filling, powder and pellet dosing (including DPI), and autoinjectors and pen assemblies.

Together, both companies serve more than 600 pharmaceutical and medical device companies, ranging from established pharmaceutical companies to early-stage innovators.

For more information, please fill out the enquiry form attached to this page.